These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34166845)

  • 1. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.
    Gülen T; Akin C; Bonadonna P; Siebenhaar F; Broesby-Olsen S; Brockow K; Niedoszytko M; Nedoszytko B; Oude Elberink HNG; Butterfield JH; Sperr WR; Alvarez-Twose I; Horny HP; Sotlar K; Schwaab J; Jawhar M; Zanotti R; Nilsson G; Lyons JJ; Carter MC; George TI; Hermine O; Gotlib J; Orfao A; Triggiani M; Reiter A; Hartmann K; Castells M; Arock M; Schwartz LB; Metcalfe DD; Valent P
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3918-3928. PubMed ID: 34166845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the Right Criteria for MCAS.
    Gulen T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium.
    Valent P; Hartmann K; Bonadonna P; Gülen T; Brockow K; Alvarez-Twose I; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Butterfield JH; Lyons JJ; Sperr WR; Greiner G; Sotlar K; Kluin-Nelemans HC; Schwaab J; Lange M; George TI; Siebenhaar F; Broesby-Olsen S; Jawhar M; Nedoszytko B; Castells M; Orfao A; Gotlib J; Reiter A; Horny HP; Triggiani M; Arock M; Metcalfe DD; Akin C
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1941-1950. PubMed ID: 35623575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
    Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
    Valent P; Hartmann K; Bonadonna P; Niedoszytko M; Triggiani M; Arock M; Brockow K
    Int Arch Allergy Immunol; 2022; 183(7):693-705. PubMed ID: 35605594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
    Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
    J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders.
    Zaghmout T; Maclachlan L; Bedi N; Gülen T
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.
    Valent P; Akin C; Arock M; Brockow K; Butterfield JH; Carter MC; Castells M; Escribano L; Hartmann K; Lieberman P; Nedoszytko B; Orfao A; Schwartz LB; Sotlar K; Sperr WR; Triggiani M; Valenta R; Horny HP; Metcalfe DD
    Int Arch Allergy Immunol; 2012; 157(3):215-25. PubMed ID: 22041891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
    Valent P; Akin C; Arock M
    Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.
    Valent P; Akin C; Bonadonna P; Hartmann K; Brockow K; Niedoszytko M; Nedoszytko B; Siebenhaar F; Sperr WR; Oude Elberink JNG; Butterfield JH; Alvarez-Twose I; Sotlar K; Reiter A; Kluin-Nelemans HC; Hermine O; Gotlib J; Broesby-Olsen S; Orfao A; Horny HP; Triggiani M; Arock M; Schwartz LB; Metcalfe DD
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1125-1133.e1. PubMed ID: 30737190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell activation syndromes: definition and classification.
    Valent P
    Allergy; 2013 Apr; 68(4):417-24. PubMed ID: 23409940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction.
    Valent P; Akin C
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1109-1114. PubMed ID: 30961836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis.
    Weiler CR
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):498-506. PubMed ID: 31470118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review.
    Sabato V; Michel M; Blank U; Ebo DG; Vitte J
    Curr Opin Allergy Clin Immunol; 2021 Oct; 21(5):426-434. PubMed ID: 34292177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
    Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
    Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
    Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O
    J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders.
    Romantowski J; Górska A; Niedoszytko M; Gulen T; Gruchała-Niedoszytko M; Nedoszytko B; Lange M; Brockow K; Arock M; Akin C; Valent P
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.